Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCue Biopharma

Cue Biopharma

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
18.99 USD 0.26 ( 1.39%)
Last update at 2026-11-09T15:22:00Z
VOLUME
112437
Market Cap
65.43M

Momentum Score

…

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
17.95
Low
19.60
High
52 Week Price Range
0.17
Low
1.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cue Biopharma is a clinical-stage biotechnology company developing targeted cellular immunotherapies intended to selectively activate antigen-specific T cells for cancer and autoimmune indications. Its proprietary platform aims to focus immune stimulation on disease-relevant T cells, and long-term growth drivers include clinical trial progression, potential expansion across antigens and strategic partnerships that may benefit commercialization. Investors may find the company attractive for its targeted approach and potential to deliver more selective immune activation if clinical data show safety and efficacy.

The most important investment risks are that Cue is pre-revenue and dependent on positive clinical trial outcomes and additional financing, exposing it to significant regulatory, execution and funding risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
18.73
Dividend Yield
-
Revenue TTM
27.47M
Revenue Per Share
0.29
Gross Profit TTM
-7.38M
Debt / Equity
0.16
ROE
-121.11%
Net Debt
-22.94M
ROCE
-92.35%
Diluted EPS TTM
-0.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.10M -40.67M -50.73M -53.01M -43.67M
Net income -26.60M -40.67M -50.73M -52.80M -44.16M
Selling general administrative 16.24M 14.59M 16.68M 16.17M 17.31M
Selling and marketing expenses - - 2.91M - -
Gross profit 23.99M 9.29M -32.61M 1.25M 14.94M
Reconciled depreciation 3.48M 2.35M 3.44M 1.81M -1.78M
Ebit -26.52M -39.88M -49.49M -53.22M -41.93M
Ebitda -23.04M -37.53M -46.05M -50.77M -43.71M
Depreciation and amortization 3.48M 2.35M 3.44M 2.46M -1.78M
Operating income -26.55M -41.50M -52.15M -53.22M -43.71M
Other operating expenses 53.99M 50.79M 57.64M 54.75M 58.65M
Interest expense 0.36M 0.80M 1.25M 0.71M 1.73M
Tax provision 0.50M 0.00M - 0.00M 0.49M
Interest income 0.81M 1.62M 2.66M 0.93M 0.05M
Net interest income 0.45M 0.83M 1.42M 0.21M 0.05M
Income tax expense 0.50M -40.67M 3.27M -0.21M 0.49M
Total revenue 27.47M 9.29M 5.49M 1.25M 14.94M
Total operating expenses 50.51M 50.79M 19.54M 54.75M 58.65M
Cost of revenue 3.48M 2.35M 38.10M - -
Total other income expense net 0.42M 0.83M 1.42M 0.21M 0.05M
Net income from continuing ops -26.60M -40.67M -50.73M -53.01M -44.16M
Net income applicable to common shares - - - -53.01M -44.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 42.21M 32.19M 61.53M 91.28M 83.40M
Other current assets 2.40M 0.81M 1.24M 0.84M 0.95M
Total liab 15.78M 14.69M 24.45M 25.60M 17.91M
Total stockholder equity 26.43M 17.50M 37.09M 65.68M 65.49M
Other current liab 7.63M 2.99M 4.14M 3.55M 4.62M
Common stock 0.10M 0.06M 0.05M 0.04M 0.03M
Capital stock 0.10M 0.06M 0.05M 0.04M 0.03M
Retained earnings -368.47M -341.86M -301.19M -250.46M -197.45M
Other assets - - - 3.39M 3.01M
Cash 27.14M 22.46M 48.51M 51.61M 64.37M
Total current liabilities 13.49M 13.69M 17.08M 11.55M 12.79M
Current deferred revenue - 0.09M 2.11M - 0.65M
Net debt -22.94M -13.58M -33.82M -32.30M -54.32M
Short term debt 1.91M 7.87M 7.33M 5.26M 4.93M
Short long term debt - 4.33M 3.96M 1.96M -
Short long term debt total 4.20M 8.88M 14.70M 19.32M 10.05M
Other stockholder equity 394.80M 359.30M 338.23M 316.19M 262.91M
Property plant equipment - - - 1.50M 2.11M
Total current assets 36.98M 25.14M 51.45M 77.19M 68.47M
Net tangible assets - - - 65.68M 65.49M
Short term investments - 0.93M 0.00M 24.67M 0.00M
Net receivables 7.45M 0.94M 1.70M 0.06M 3.14M
Long term debt - - 4.20M 8.03M -
Inventory - - 0.00M - -
Accounts payable 3.95M 2.82M 3.50M 2.73M 2.59M
Accumulated other comprehensive income - - - -0.10M -
Common stock total equity - - - 0.04M 0.03M
Retained earnings total equity - - - -250.46M -197.45M
Non currrent assets other 0.76M 2.21M 2.81M 3.39M 3.01M
Non current assets total 5.23M 7.05M 10.08M 14.10M 14.93M
Capital lease obligations 4.20M 4.54M 6.53M 9.32M 10.05M
Long term debt total - - - 8.03M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.21M 0.03M 25.00M -29.45M 10.00M
Change to liabilities - - - -0.99M 2.35M
Total cashflows from investing activities 0.07M 0.03M 25.00M -24.61M 9.11M
Net borrowings -4.50M -4.00M -2.00M 14.56M 10.00M
Total cash from financing activities 26.29M 10.24M 11.86M 53.66M 19.23M
Change to operating activities - - - -2.17M -3.18M
Net income -26.60M -40.67M -50.73M -53.01M -44.16M
Change in cash 4.68M -26.05M -3.10M -12.76M -10.50M
Begin period cash flow 22.61M 48.66M 51.76M 64.52M 75.02M
End period cash flow 27.29M 22.61M 48.66M 51.76M 64.52M
Total cash from operating activities -21.69M -36.33M -39.96M -41.81M -38.84M
Issuance of capital stock 30.79M 14.22M 13.39M 39.30M 17.38M
Depreciation 0.96M 2.35M 3.44M 1.81M -1.78M
Other cashflows from investing activities 0.21M 0.10M 0.00M 5.01M 10.02M
Change to inventory - - - - 4.79M
Change to account receivables -6.50M 0.75M -1.64M 3.09M -1.73M
Sale purchase of stock - - - 22.50M 19.23M
Other cashflows from financing activities 26.29M 0.02M 0.47M 14.50M 1.85M
Change to netincome - - - 9.50M 11.49M
Capital expenditures 0.18M 0.07M 0.00M 0.17M 0.91M
Change receivables - - - 3.09M -1.73M
Cash flows other operating - - - -1.03M -1.98M
Cash and cash equivalents changes - - - -12.76M -10.50M
Change in working capital -3.29M -4.92M -0.93M 0.36M -4.39M
Stock based compensation 4.74M 6.85M 8.18M 9.50M 11.52M
Other non cash items 2.51M 0.07M 0.09M -0.45M -0.03M
Free cash flow -21.86M -36.40M -39.96M -41.98M -39.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CUE
Cue Biopharma		 0.26
1.39%		 18.99 - - 2.38 3.14 2.19 -1.76
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

40 Guest Street, Boston, MA, United States, 02135

617 949 2680

https://www.cuebiopharma.com

29

Name Title Year Born
Mr. Daniel R. Passeri J.D., M.Sc., MSc. CEO & Director 1961
Dr. Anish Suri Ph.D. Pres & Chief Scientific Officer 1974
Ms. Kerri-Ann Millar Chief Financial Officer 1970
Dr. Ronald D. Seidel III, Ph.D. Co-Founder 1976
Dr. Rodolfo J. Chaparro Co-Founder & Sr. Advisor 1973
Dr. Steven C. Almo Co-Founder and Chairman of Scientific & Clinical Advisory Board 1961
George B. Zavoico Ph.D. VP of Investor Relations & Corp. Devel. NA
Mr. Colin G. Sandercock J.D., MSE Sr. VP, Gen. Counsel & Sec. 1957
Dr. Kenneth J. Pienta M.D. Acting Chief Medical Officer 1960
Dr. Matteo Levisetti M.D. Sr. VP of Clinical Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…